Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Evidence against hypothalamic-pituitary-adrenal axis suppression in the antidiabetic action of leptin
Gregory J. Morton, … , Miles E. Matsen, Michael W. Schwartz
Gregory J. Morton, … , Miles E. Matsen, Michael W. Schwartz
Published November 3, 2015
Citation Information: J Clin Invest. 2015;125(12):4587-4591. https://doi.org/10.1172/JCI82723.
View: Text | PDF
Brief Report Metabolism Neuroscience

Evidence against hypothalamic-pituitary-adrenal axis suppression in the antidiabetic action of leptin

  • Text
  • PDF
Abstract

Leptin administration restores euglycemia in rodents with severe insulin-deficient diabetes, and recent studies to explain this phenomenon have focused on the ability of leptin to normalize excessive hypothalamic-pituitary-adrenal (HPA) axis activity. Here, we employed a streptozotocin-induced rat model (STZ-DM) of uncontrolled insulin-deficient diabetes mellitus (uDM) to investigate the contribution of HPA axis suppression to leptin-mediated glucose lowering. Specifically, we asked if HPA axis activation is required for diabetic hyperglycemia, whether HPA axis normalization can be achieved using a dose of leptin below that needed to normalize glycemia, and if the ability of leptin to lower plasma glucocorticoid levels is required for its antidiabetic action. In STZ-DM rats, neither adrenalectomy-induced (ADX-induced) glucocorticoid deficiency nor pharmacological glucocorticoid receptor blockade lowered elevated blood glucose levels. Although elevated plasma levels of corticosterone were normalized by i.v. leptin infusion at a dose that raises low plasma levels into the physiological range, diabetic hyperglycemia was not altered. Lastly, the potent glucose-lowering effect of continuous intracerebroventricular leptin infusion was not impacted by systemic administration of corticosterone at a dose that maintained elevated plasma levels characteristic of STZ-DM. We conclude that, although restoring low plasma leptin levels into the physiological range effectively normalizes increased HPA axis activity in rats with uDM, this effect is neither necessary nor sufficient to explain leptin’s antidiabetic action.

Authors

Gregory J. Morton, Thomas H. Meek, Miles E. Matsen, Michael W. Schwartz

×

Figure 3

Suppression of hypercorticosteronemia is not required for leptin’s antidiabetic effects in STZ-DM.

Options: View larger image (or click on image) Download as PowerPoint
Suppression of hypercorticosteronemia is not required for leptin’s antid...
(A–D) Three-hour fasted plasma insulin and leptin (A), corticosterone (B) and ACTH levels (C) obtained mid-light cycle (13:00), and (D) daily-fed blood glucose levels in surgical ADX (ADX-STZ) diabetic rats that received both continuous icv infusion of leptin (beginning on day 4; ADX-STZ-lep), and either a low dose (physiological replacement; 35 mg pellet; Cort-low) or a high dose of corticosterone s.c. (to raise plasma corticosterone levels into the range of rats with STZ-DM; 2 × 35 mg pellet; Cort-high) (n = 8–11/group). Data represent mean ± SEM. Data were analyzed by a 2-tailed, unpaired Student’s t test. *P < 0.05 vs. Cort-low.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts